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Introduction

Approximately 32,000 pancreatic neoplasms are diagnosed in the
United States annually.1 Currently, carcinoma of the pancreas is
the fourth most common cause of cancer death in both men
and women in this country, after cancers of the lung, breast/
prostate, and colon. The most common presenting symptoms
of pancreatic cancers are epigastric pain, obstructive jaundice,
and weight loss.1 However, since pancreatic cancer is frequently
metastatic when diagnosed, it may uncommonly present with
findings characteristic of the site of spread.

Case Presentation

A 42 year-old Caucasian female with no significant past medical
history presented with a four-month history of daily hemoptysis
associated with a productive cough and a two-week history of
jaundice and gray stools. The initial evaluation for hemoptysis,
performed at an outside hospital approximately three months
prior to presentation included a normal chest radiograph and
negative PPD. Two weeks prior to admission, the patient presented
to an outside hospital complaining of epigastric pain for one
week, as well as new onset jaundice and persistent hemoptysis.
Per the patient, an abdominal ultrasound performed at that time

revealed a pancreatic mass. She presented shortly thereafter to our
hospital with worsening hemoptysis, epigastric and right upper
quadrant pain, and jaundice. She described the abdominal pain
as constant and dull, with an intermittent stabbing component.
The pain was aggravated when lying down and relieved by
oxycodone-acetaminophen. She also reported generalized fatigue
and a five-pound weight loss over three weeks.
She denied fever, chills, night sweats, chest pain, shortness-ofbreath, nausea, vomiting, or diarrhea. She has no known drug
allergies. Her only medication was oxycodone-acetaminophen
which was started for abdominal pain during the previous
hospital visit. She has no history of abdominal or other surgeries.
She consumes three to four drinks of alcohol per week during
the past two years and has smoked approximately one pack of
cigarettes per day for the past 25 years. She used cocaine on
occasion more than 10 years ago. She denied intravenous drug
use. Her mother, a smoker, died from small cell lung cancer, and
her father died from prostate cancer. She denied recent travel,
as well as known exposure to individuals with tuberculosis,
asbestos, or other inhaled chemicals.

Figure 1. PA and lateral chest radiographs shows showed no evidence of infiltrates, effusions, or masses.
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Hospital Course

Initial examination revealed a jaundiced but well-appearing
middle-aged woman in no acute distress. Vital signs revealed a
temperature of 98.7° Fahrenheit, blood pressure 92/62 mm Hg,
heart rate 70 beats/minute, respiratory rate of 18 breaths/minute,
and oxygen saturation of 96% while the patient was breathing
ambient air. The sclerae were icteric. The lungs were clear to
auscultation bilaterally without wheezes, rales, or rhonchi.
Abdominal exam revealed tenderness on palpation of the right
upper quadrant and epigastrium without rebound tenderness
or guarding. No Murphy`s sign was detected. The skin was
jaundiced without rashes, spider angiomata, or palmar erythema.
The remainder of the physical examination was unremarkable.
The results of the laboratory tests were significant for total
bilirubin 10.8 mg/dL, direct bilirubin 4.9 mg/dL, AST 148 IU/L,
ALT 196 IU/L, and alkaline phosphatase 225 IU/L. CEA was 1.1
ng/mL (normal range: 0.0-5.0 ng/mL) and CA 19-9 was 12 ng/
mL (normal range: 0.0-36.0 U/mL). Her complete blood count,
basic metabolic panel including creatinine, protein, albumin,
amylase, lipase, PT, and PTT were within normal limits.

Figure 2. CT thorax with contrast illustrates a cavitary lesion in
the anterior segment of the left upper lobe (arrow).

A chest radiograph obtained on admission showed no evidence
of infiltrates, effusions, or masses (Figure 1). A chest CT with
contrast performed at an outside hospital two weeks prior to
presentation revealed a cavitary lesion in the anterior segment
of the left upper lobe. The lesion was confirmed by repeat CT
scan (Figure 2) and measured 2.6 X 2.5 cm, with no marked
changes in size or appearance from the prior study. Several
small lung nodules were noted as well. In addition, enlarged
mediastinal lymph nodes measuring 10 mm in diameter were
noted in the hila bilaterally. Multi-detector abdominal CT with
contrast (Figure 3) revealed a pancreatic head mass measuring
3.5 X 3.3 cm, with abdominal lymphadenopathy, and intra- and
extra-hepatic biliary ductal dilatation.
Based on these findings, the initial differential diagnosis included
a metastatic neoplasm of either pulmonary or pancreatic origin.
Disseminated tuberculosis or other bacterial or fungal infection,
as well as a vasculitic process, were also considered. Antineutrophil Cytoplasmic Antibody (ANCA) serologies were
obtained and were negative. ESR was 22 mm/hr (normal range:
0-15 mm/hr) and CRP was 0.7 mg/l (normal range: <12 mg/L).

Figure 3. Multi-detector CT abdomen and pelvis with contrast
detects a hypodense mass in the head of the pancreas (arrow).

For diagnostic and therapeutic purposes, endoscopic retrograde
cholangio-pancreatography (ERCP) was performed. A common
bile duct (CBD) stricture was noted, and brush cytology of the
CBD was obtained. Subsequently, an expandable metal stent
was placed in the CBD after sphincterotomy. In order to further
evaluate the pancreatic mass, endoscopic ultrasound (EUS) was
performed, and fine needle aspiration (FNA) biopsy of the mass
was performed. Bronchoscopy was performed to further evaluate
the cavitary lung lesion noted on CT scan. Bronchoalveolar
lavage (BAL) and bronchial brushings were sent for cytology,
Gram stain, and culture. Endobronchial ultrasonography-
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lesions within the left upper lobe of the lung, left adrenal gland,
and L1 vertebral body. The patient later initiated chemotherapy
as an outpatient for palliation of widely metastatic pancreatic
cancer. She was given a final diagnosis of primary pancreatic
adenocarcinoma metastatic to the lung, adrenal gland, and
spine.

Discussion

Pancreatic cancer is notoriously aggressive. Indeed, surgically
resectable cases on presentation represent the minority:
approximately 10% to 15%. Pancreatic neoplasms metastasize by
hematogenous and lymphatic routes. Locally, the celiac plexus,
superior mesenteric artery, portal vein, and ligament of Treitz
are common sites of spread. The liver appears to be the most
frequent target of distant metastasis, as well as the peritoneum.
The lung is also a common target. Lung metastases were present
in greater than 50% of patients with metastatic pancreatic cancer
in one study.2

Figure 4. CT-guided biopsy of anterior lung mass.
guided biopsy was attempted; however, the biopsy was unable to
be obtained due to excessive coughing during the procedure.
Cytologic analysis of the CBD brushings was negative for
malignant cells. However, the FNA of the pancreatic head
mass revealed features consistent with pancreatic ductal
adenocarcinoma. The microbiology and pathology from the
bronchoscopy samples were unrevealing: BAL fluid cultures
were negative for bacteria and fungus, and the bronchial brush
cytology revealed benign epithelial cells. Thus, a definitive
diagnosis of the cavitary lung lesion was lacking.
The patient’s jaundice and abdominal pain improved following
the placement of the CBD stent. She was discharged home
with a presumptive diagnosis of metastatic pancreatic cancer,
and arrangements to follow-up with medical oncology. Four
days later, the patient was re-admitted for complaints of fever
and headache. Brain MRI and bone scan showed no evidence
of metastasis to those sites. The patient’s hospital course was
complicated by E. coli bacteremia, likely secondary due to ERCP
and CBD stent placement. Having been treated with intravenous
antibiotics, and with subsequent negative blood cultures, she was
discharged to home with plans to undergo CT-guided biopsy of
the lung lesion as an outpatient. Ten days after discharge, biopsy
of the lung mass was successfully performed with CT guidance
(Figure 4). Pathology revealed malignant cells morphologically
similar to those obtained by FNA of the pancreatic mass. In order
to fully elucidate the extent of metastasis, positron emission
tomographic scanning was performed, which confirmed the
presence of a hypermetabolic mass in the pancreas, as well as
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It is rare for metastatic pancreatic cancer to present initially with
pulmonary symptoms. Nevertheless, there are case reports of
pancreatic cancer “masquerading” as bronchogenic carcinoma,
with initial symptoms including cough and dyspnea, as well
as those related to paraneoplastic syndromes, i.e., Horner’s
syndrome.3 It has been shown that pancreatic metastases can be
radiographically indistinguishable from primary bronchogenic
carcinomas,4 highlighting the importance of obtaining biopsy
for tissue diagnosis and to guide treatment.
The treatment of pancreatic cancer is broadly based on staging
of the disease to determine resectability. With the exception of
lymph node spread restricted to the surgical field, metastasis
renders pancreatic cancer unresectable. The median survival
after diagnosis is extremely poor in the case of unresectable
pancreatic cancer: approximately three to five months.1 Surgical
resection via partial pancreaticoduodenectomy (i.e., the Whipple
procedure), typically with adjuvant chemotherapy, is the only
treatment modality with any meaningful survival benefit. Median
survival can be extended to 12 to 18 months with surgery and
still further in conjunction with chemotherapy.5 The treatment
of unresectable pancreatic cancer, including distantly metastatic
disease, is essentially palliative and entails management of
symptoms, including pain, jaundice, and malabsorption.1
The most common findings in the setting of pancreatic cancer
include jaundice and abdominal pain. Other findings include
Courvoisier’s sign (i.e., a palpable nontender gallbladder)
and Trousseau’s syndrome (i.e., superficial and deep venous
thrombosis), as well as more vague symptoms such as fatigue
and weight loss.6 The presentation is often suggestive of the
site of the pancreatic mass. Tumors of the head of the pancreas
tend to present with jaundice. Pain is often a later finding,
associated with tumors of the pancreatic body and tail. Back
pain is an ominous sign, as it may indicate local spread to the
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celiac neuroplexus posterior to the pancreas. The present case
is unusual in that pulmonary symptomatology preceded the
more typical findings of abdominal pain and jaundice. Because
pancreatic head cancers often impinge on the CBD and cause
jaundice, these cancers can sometimes be detected at an earlier,
less advanced stage than cancers of the body or tail, which are all
frequently metastatic to distant sites before pain in the abdomen
or the back emerges.
In addition to metastatic pancreatic or lung cancer, our
differential diagnosis for the concurrent findings of a cavitary
lung lesion and pancreatic mass included atypical infections, such
as mycobacterial and fungal infections, other granulomatous
diseases, and systemic vasculitides, such as Wegener’s
granulomatosis. Tuberculosis was a consideration in the present
case, although less likely in the context a negative PPD and lack
of a suggestive exposure history. Sarcoidosis is well known to
involve multiple organs, including the respiratory system, skin,
eye, heart, and liver. There are case reports of rare involvement
of the pancreas, causing symptoms similar to pancreatic cancer.7
Wegener’s granulomatosis has been reported to manifest like
pancreatic carcinoma as well.8 Interestingly, the patient in the
present case reported intermittent sinus symptoms, but negative
ANCA serologies and a lack of renal involvement made this
hypothesis less likely. Ultimately, tissue sampling of the lung
and pancreas masses by CT guidance and EUS-FNA proved
critical in establishing a definitive diagnosis in this case.

In summary, the current case represents an uncommon presentation
of metastatic pancreatic adenocarcinoma, characterized by
jaundice and abdominal pain preceded by a prolonged period of
respiratory symptoms alone.
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